Funded in 2014 and resulting from the "Investments for the Future" French program, SATT Paris-Saclay is the Technology Transfer Acceleration Company of the Paris-Saclay Cluster.
A common player in both entities - Paris-Saclay University and Institut Polytechnique de Paris - the SATThas an investment capacity of 66 million euros over 10 years to finance and support the development of research work from the territory and the technology transfer to markets.
SATT Paris-Saclay supports the BB-100 lead product validation through two grants, POC'Up and Maturation, for a total of 616K€.
The Commissariat à l'énergie atomique et aux énergies alternatives (CEA) is a public scientific, technical and industrial research body (EPIC). A French major player in research, development and innovation, the CEAoperates in four areas, defense and security, low-carbon energies (nuclear and renewable), technological research for industry, fundamental research in science of matter and life sciences.
CEA Paris-Saclay has awarded a worldwide exclusive licence to Blue Bees Therapeutics on i.Ther technology, and hosts the company's R&D laboratory
Bpifrancefinances and supports companies - at each stage of their development - with loans, guarantees, aid for innovation and equity. In doing so, Bpifranceacts in support of public policies conducted by the Franch government and the Regions.
Bpifrancesupports Blue Bees Therapeutics through grants, including BFTE and i.Lab, for a total of 465K€.
Ce site utilise des cookies pour permettre le bon fonctionnement, la sécurité, et vous offrir la meilleure expérience utilisateur possible.
Vous pouvez personnaliser vos préférences en matière de cookies ici. Activez ou désactivez les catégories suivantes et enregistrez votre sélection.